Headlines about Integra Lifesciences (NASDAQ:IART) have trended somewhat positive this week, InfoTrie Sentiment Analysis reports. The research firm rates the sentiment of media coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Integra Lifesciences earned a media sentiment score of 1.46 on their scale. InfoTrie also gave press coverage about the life sciences company an news buzz score of 10 out of 10, indicating that recent media coverage is extremely likely to have an effect on the company’s share price in the immediate future.

Shares of IART stock opened at $49.96 on Friday. Integra Lifesciences has a 1-year low of $45.96 and a 1-year high of $67.50. The company has a current ratio of 3.20, a quick ratio of 2.08 and a debt-to-equity ratio of 1.04. The firm has a market cap of $4.39 billion, a PE ratio of 25.75, a price-to-earnings-growth ratio of 1.60 and a beta of 0.76.

Integra Lifesciences (NASDAQ:IART) last issued its quarterly earnings results on Wednesday, October 31st. The life sciences company reported $0.59 earnings per share for the quarter, meeting analysts’ consensus estimates of $0.59. Integra Lifesciences had a return on equity of 16.99% and a net margin of 5.49%. The business had revenue of $365.85 million for the quarter, compared to the consensus estimate of $367.89 million. During the same quarter in the previous year, the company posted $0.45 earnings per share. Integra Lifesciences’s revenue for the quarter was up 31.2% compared to the same quarter last year. On average, equities research analysts anticipate that Integra Lifesciences will post 2.39 EPS for the current year.

A number of equities analysts recently issued reports on the company. Oppenheimer restated a “buy” rating on shares of Integra Lifesciences in a report on Tuesday, October 2nd. Zacks Investment Research downgraded Integra Lifesciences from a “hold” rating to a “sell” rating in a report on Tuesday, September 25th. BTIG Research reiterated a “buy” rating and set a $69.00 price target on shares of Integra Lifesciences in a report on Wednesday, September 12th. BidaskClub upgraded Integra Lifesciences from a “hold” rating to a “buy” rating in a report on Friday, October 19th. Finally, Morgan Stanley set a $68.00 price target on Integra Lifesciences and gave the company a “hold” rating in a report on Thursday, October 11th. One investment analyst has rated the stock with a sell rating, eleven have given a hold rating and four have assigned a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and a consensus price target of $61.62.

In related news, major shareholder Richard E. Caruso sold 46,676 shares of Integra Lifesciences stock in a transaction on Wednesday, October 17th. The stock was sold at an average price of $63.19, for a total transaction of $2,949,456.44. Following the completion of the sale, the insider now owns 134,134 shares of the company’s stock, valued at $8,475,927.46. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, Director Barbara B. Hill acquired 3,705 shares of Integra Lifesciences stock in a transaction that occurred on Monday, November 5th. The shares were purchased at an average cost of $53.90 per share, with a total value of $199,699.50. Following the transaction, the director now owns 63,381 shares of the company’s stock, valued at approximately $3,416,235.90. The disclosure for this purchase can be found here. 5.10% of the stock is currently owned by company insiders.

ILLEGAL ACTIVITY NOTICE: “Integra Lifesciences (IART) Given News Sentiment Score of 1.46” was first posted by Watch List News and is the property of of Watch List News. If you are accessing this piece on another publication, it was copied illegally and republished in violation of international copyright laws. The correct version of this piece can be viewed at https://www.watchlistnews.com/integra-lifesciences-iart-given-news-sentiment-score-of-1-46/2668939.html.

About Integra Lifesciences

Integra LifeSciences Holdings Corporation develops, manufactures, and markets surgical implants and medical instruments for use in neurosurgery, extremity reconstruction, orthopedics, and general surgery. The company operates in two segments, Codman Specialty Surgical, and Orthopedics and Tissue Technologies.

Read More: SEC Filing

Receive News & Ratings for Integra Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Integra Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.